The acquisition of Reverse Medical is expected to complement Covidien plc's (COV) existing portfolio of vascular technologies, lending it a competitive edge in the worldwide vascular embolization market....
from Content Keyword RSS http://ift.tt/1qrtEvU
via IFTTT
from Content Keyword RSS http://ift.tt/1qrtEvU
via IFTTT
No comments:
Post a Comment